Mutations in genes in both pathways, such as adenomatous polyposis coli (APC) and KRAS, which occur in as many as 90% and in 40–50%1,2, respectively, of human colorectal cancers (CRCs), are known to be involved in the initiation and progression of CRC. The gene discussed is APC; the disease is colorectal carcinoma.